Abstract
Objective: To provide recommendations for creating and sustaining a treatment-resistant depression (TRD) consultation program at an academic health center. This is a complementary manuscript to Part II, which discusses critical elements of the assessment package for such subspecialized consultations.
Participants: Participants were a working group of 12 clinicians, researchers, administrators, and patient advocates from the National Network of Depression Centers (NNDC) TRD Task Group.
Evidence: The recommendations are based on expert opinion. TRD consultation programs can offer an individualized treatment roadmap to be implemented by the patient and their providers with the goal of maximizing the likelihood of response or full remission of symptoms. However, there is currently no published work addressing the practical and logistical considerations for establishing such programs. This consensus statement puts forth a set of recommendations that could serve as a basis for future empirical work.
Consensus Process: Members of the working group provided written descriptions of relevant procedures used at their institutions, which were used during a day-long in-person forum to achieve consensus on recommendations for each major aspect of a TRD consultation program. Subgroups were formed to draft recommendations, and points of disagreement were resolved at subsequent meetings of the full working group.
Conclusions: We describe key practical considerations, including systems-level and financial issues; equity and access to TRD care for a diverse patient population; selecting a target population and facilitating the referral process; the product of the consultation; communication between the program, patient, and community providers; and postconsultation care and contact.
J Clin Psychiatry 2025;86(2):24cs15335
Author affiliations are listed at the end of this article.
Continue Reading...
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
References (60)
- World Health Organization. Depression. World Health Organization; 2021. Accessed March 17, 2023. https://www.who.int/en/news-room/fact-sheets/detail/depression
- Ettman CK, Abdalla SM, Cohen GH, et al. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686. CrossRef
- Bueno-Notivol J, Gracia-García P, Olaya B, et al. Prevalence of depression during the COVID-19 outbreak: a meta-analysis of community-based studies. Int J Clin Health Psychol. 2021;21(1):100196.
- Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26(3):222–232.
- Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150. CrossRef
- Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17–25.
- Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161(1):163–165. CrossRef
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. CrossRef
- Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53(2):109–118. CrossRef
- Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699.
- Yager J, Langsley DG. The evolving subspecialization of psychiatry: implications for the profession. Am J Psychiatry. 1987;144(11):1461–1465.
- Shore JH. Order and chaos: subspecialization and american psychiatry. Acad Psychiatry. 1993;17(1):12–20.
- Bhugra D, Tasman A, Pathare S, et al. The WPA-lancet psychiatry commission on the future of psychiatry. Lancet Psychiatry. 2017;4(10):775–818. CrossRef
- Li J, Burson RC, Clapp JT, et al. Centers of excellence: are there standards? Healthc (Amst). 2020;8(1):100388. CrossRef
- Mehrotra A, Dimick JB. Ensuring excellence in centers of excellence programs. Ann Surg. 2015;261(2):237–239. CrossRef
- Manyazewal T, Woldeamanuel Y, Oppenheim C, et al. Conceptualising centres of excellence: a scoping review of global evidence. BMJ Open. 2022;12(2):e050419. CrossRef
- Elrod JK, Fortenberry JL Jr. Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017;17(suppl 1):425. CrossRef
- Pronovost PJ, Ata GJ, Carson B, et al. What is a center of excellence? Popul Health Manag. 2022;25(4):561–567. CrossRef
- Vieta E. Bipolar units and programmes: are they really needed? World Psychiatry. 2011;10(2):152. CrossRef
- Greden JF. The National Network of Depression Centers: progress through partnership. Depress Anxiety. 2011;28(8):615–621. CrossRef
- Fournier JC, Voytenko VL, Docherty AR, et al. Developing a treatment-resistant depression consultation program, part 2: assessment. J Clin Psychiatry. 2025;86(2):24cs15336.
- Parikh SV, Lopez D, Vande Voort JL, et al. Developing an IV ketamine clinic for treatment-resistant depression: a primer. Psychopharmacol Bull. 2021;51(3):109–124.
- Bishop TF, Press MJ, Keyhani S, et al. Acceptance of insurance by psychiatrists and the implications for access to mental health care. JAMA Psychiatry. 2014;71(2):176–181. CrossRef
- Byrow Y, Pajak R, Specker P, et al. Perceptions of mental health and perceived barriers to mental health help-seeking amongst refugees: a systematic review. Clin Psychol Rev. 2020;75:101812. CrossRef
- Cyr ME, Etchin AG, Guthrie BJ, et al. Access to specialty healthcare in urban versus rural US populations: a systematic literature review. BMC Health Serv Res. 2019;19(1):974. CrossRef
- Mongelli F, Georgakopoulos P, Pato MT. Challenges and opportunities to meet the mental health needs of underserved and disenfranchised populations in the United States. Focus. 2020;18(1):16–24. CrossRef
- Moroz N, Moroz I, D’Angelo MS. Mental health services in Canada: barriers and cost effective solutions to increase access. Healthc Manage Forum. 2020;33(6):282–287. CrossRef
- National Center for Health Workforce Analysis. Behavioral Health Workforce. Health Workforce Analysis; 2023. Accessed May 5, 2024. https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/Behavioral-Health-Workforce-Brief-2023.pdf
- Duffy FF, West JC, Wilk J, et al. Mental health practitioners and trainees. In Manderscheid RW, Berry JT, eds. Mental Health, United States, 2004. DHHS Pub No. (SMA)-06-4195. Substance Abuse and Mental Health Services Administration; 2006:256–309.
- Keuroghlian AS, Marcus PH, Neufeld J, et al. Telehealth for psychiatry and mental healthcare can improve access and patient outcomes. Nat Med. 2023;29(11):2698–2700. CrossRef
- Ettman CK, Brantner CL, Albert M, et al. Trends in telepsychiatry and in-person psychiatric care for depression in an academic health system, 2017-2022. Psychiatr Serv. 2024;75(2):178–181. CrossRef
- Gamoran J, Xu Y, Buinewicz SAP, et al. An examination of depression severity and treatment adherence among racially and ethnically minoritized, low-income individuals during the COVID-19 transition to telehealth. Psychiatry Res. 2024;342:116221. CrossRef
- Shaker AA, Austin SF, Storebø OJ, et al. Psychiatric treatment conducted via telemedicine versus in-person modality in posttraumatic stress disorder, mood disorders, and anxiety disorders: systematic review and meta-analysis. JMIR Ment Health. 2023;10:e44790.
- van der Merwe M, Atkins T, Scott AM, et al. Diagnostic assessment via live telehealth (phone or video) versus face-to-face for the diagnoses of psychiatric conditions: a systematic review. J Clin Psychiatry. 2024;85(4):24r15296.
- Salerno SM, Hurst FP, Halvorson S, et al. Principles of effective consultation: an update for the 21st-century consultant. Arch Intern Med. 2007;167(3):271–275.
- Balestri M, Calati R, Souery D, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–232. CrossRef
- Bennabi D, Aouizerate B, El-Hage W, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015;171:137–141. CrossRef
- Fernando I, Cohen M, Henskens F. A systematic approach to clinical reasoning in psychiatry. Australas Psychiatry. 2013;21(3):224–230. CrossRef
- Haddad PM, Talbot PS, Anderson IM, et al. Managing inadequate antidepressant response in depressive illness. Br Med Bull. 2015;115(1):183–201. CrossRef
- Parker GB, Malhi GS, Crawford JG, et al. Identifying “paradigm failures” contributing to treatment-resistant depression. J Affect Disord. 2005;87(2–3):185–191. CrossRef
- Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070.
- Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(suppl 1):S9–S13. CrossRef
- Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2):PCC.09r00826.
- Haynes SN, Williams AE. Case formulation and design of behavioral treatment programs. Eur J Psychol Assess. 2003;19(3):164–174. CrossRef
- Macneil CA, Hasty MK, Conus P, et al. Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. BMC Med. 2012;10:111. CrossRef
- Bergner RM. Characteristics of optimal clinical CFs. The linchpin concept. Am J Psychother. 1998;52(3):287–300.
- Westermeyer JJ, Weiss RD, Ziedonis DM. Integrated Treatment for Mood and Substance Use Disorders. JHU Press; 2003.
- Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012;35(1):249–265. CrossRef
- Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):18–25.
- Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131–161. CrossRef
- Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother. 2011;11(7):961–970. CrossRef
- Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111–126. CrossRef
- Lipsman N, Sankar T, Downar J, et al. Neuromodulation for treatment-refractory major depressive disorder. CMAJ. 2014;186(1):33–39. CrossRef
- Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(suppl 6):16–25.
- Sarris J, O’Neil A, Coulson CE, et al. Lifestyle medicine for depression. BMC Psychiatry. 2014;14:107. CrossRef
- van Bronswijk S, Moopen N, Beijers L, et al. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychol Med. 2019;49(3):366–379. CrossRef
- Hong RH, Murphy JK, Michalak EE, et al. Implementing measurement-based care for depression: practical solutions for psychiatrists and primary care physicians. Neuropsychiatr Dis Treat. 2021;17:79–90. CrossRef
- Mayes TL, Deane AE, Aramburu H, et al. Improving identification and treatment outcomes of treatment-resistant depression through measurement-based care. Psychiatr Clin North Am. 2023;46(2):227–245. CrossRef
- Lewis CC, Boyd M, Puspitasari A, et al. Implementing measurement-based care in behavioral health: a review. JAMA Psychiatry. 2019;76(3):324–335.
- Rodriguez JA, Clark CR, Bates DW. Digital health equity as a necessity in the 21st century cures act era. JAMA. 2020;323(23):2381–2382. CrossRef
Buy PDF for $40
Please sign in or purchase this PDF for $40.
Save
Share
Cite
Subscribe Now
Already a member? Login
